Combination Chemotherapy With Irinotecan and Cisplatin in Pretreated Patients With Unresectable or Recurrent Gastric Cancer

Gastric Cancer - Germany
doi 10.1007/s10120-006-0379-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Efficacy of Irinotecan as Third-Line Chemotherapy for Unresectable or Recurrent Gastric Cancer

In Vivo
BiochemistryMedicineGeneticsPharmacologyMolecular Biology
2020English

Phase II Study on the Combination of Irinotecan Plus Cisplatin as a Second-Line Therapy in Patients With Advanced or Recurrent Gastric Cancer

Molecular and Clinical Oncology
Cancer ResearchOncology
2013English

Phase I/Ii Studies of Combination Chemotherapy With S-1 and Platinum in Patients With Previously Untreated Metastatic or Recurrent Gastric Cancer

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2009English

Phase I/Ii Study of S-1 Combined With Paclitaxel in Patients With Unresectable and/or Recurrent Advanced Gastric Cancer

British Journal of Cancer
Cancer ResearchOncology
2006English

First-Line Single-Agent Chemotherapy for Patients With Recurrent or Metastatic Gastric Cancer With Poor Performance Status

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2012English

Combination Chemotherapy With Paclitaxel, Cisplatin and Fluorouracil for Patients With Advanced and Metastatic Gastric or Esophagogastric Junction Adenocarcinoma: A Multicenter Prospective Study

Chinese Journal of Cancer Research
Cancer ResearchOncology
2012English

Triplet Chemotherapy Combination With Cisplatin, Gemcitabine and Docetaxel in Patients With Chemotherapy‑naive Advanced Non-Small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2013English

Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched With Patients Treated With Parenteral Chemotherapy

Anticancer Research
MedicineCancer ResearchOncology
2016English

Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S‐1/Oxaliplatin/Irinotecan) in Patients With Unresectable Pancreatic Ductal Adenocarcinoma

Oncologist
Cancer ResearchMedicineOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy